Kula Xiéhé Qílín, AML frontline therapy "Givtominib" combination therapy demonstrated high remission rates and MRD-negative rates in Phase 1 clinical trials

Kura Oncology ($KURA) and Concordia Kirin will announce updated data on the frontline treatment candidate “Ziftometinib” combination therapy for acute myeloid leukemia (AML) at the European Hematology Association (EHA) 2026.
This release is based on the results of the Phase 1 “KOMET-007” trial involving 99 patients with newly diagnosed NPM1 mutations and KMT2A rearrangements, which garnered attention for confirming high remission rates and deep molecular remission in early treatment stages.

According to the announced results, in the Ziftometinib combined with standard induction chemotherapy “7+3” regimen group, the composite complete remission rate (CRc) was 96% for NPM1 mutation patients and 90% for KMT2A rearrangement patients.
Both groups had MRD-negative rates exceeding 80%.
MRD negativity refers to a state where cancer cells are nearly undetectable, serving as a key indicator of the depth of treatment response.

The significance of this data lies not only in demonstrating an initial remission but also in showing the “durability” of the remission.
Since AML is classified as a high relapse risk hematologic cancer, how long this remission can be maintained becomes a critical standard for subsequent development and commercial evaluation.
Particularly, NPM1 mutations and KMT2A rearrangements are distinct molecular subtypes of AML, and personalized treatment strategies for different patient groups have always been highly valued.

Proceeding to Phase 3 trials to accelerate development

Kura Oncology and Concordia Kirin stated that, based on these Phase 1 results, they are initiating registration for the Phase 3 “KOMET-017” trial.
If the high CRc rate and MRD negativity observed in early clinical trials can be reproduced in later stages, Ziftometinib could potentially become a competitive option for first-line treatment of AML with specific gene mutations.

The two companies also plan to hold an online investor briefing on June 3, 2026.
The event is expected to provide detailed information on the data released at EHA, as well as patient follow-up results, duration of remission, safety profile, and future development timeline.
Markets often use such briefings to confirm insights and development strategies that are more important than mere numbers.

Focus on whether it can change the AML treatment landscape

The results of KOMET-007 indicate that the AML drug development competition has shifted beyond simply improving survival, moving toward faster, deeper remissions and relapse suppression.
If Ziftometinib combination therapy can sustain this trend in later clinical stages, it may become a representative case of precision medicine based on genetic mutations.
However, final evaluation may still require longer follow-up and confirmation from Phase 3 results.

TP AI Notice: This article is summarized based on the TokenPost.ai language model.
The main content may be omitted or inconsistent with facts.